Anjani Muthyala
Internal Medicine · Worcester, MANPI 1053965293
Payments from drug & device makers
Across 238 payments — averaging $55.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$3K
- Philips North America LLC$2K
- Abiomed$2K
- Abbott$800
- Johnson & Johnson$690
- E.r. Squibb & Sons, L.L.C.$475
- plus $5K from 34 others
What the payments were for
- Travel & lodging$3,17724%
- Food & beverage$9,77473%
- Education$3623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$1,933
- Sentus$426
- Plexa ProMRI$426
- Solia$426
- Edora 8 DR-T$426
- Acticor 7 VR-T DX$426
- Impella$363
- ENSITE$362
- XARELTO$255
- Barostim Neo System$154
- SYMPLICITY G3$148
- Kerendia$133
- OPTIS$132
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$125
- JARDIANCE$125
- FUROSCIX$125
- Rivacor 7 DR-T$125
- CAMZYOS$119
- LifeVest$117
- Optitorque$105
How this compares
$13,313 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $26,444 |
| EntrestoSacubitril/Valsartan | 13 | $18,172 |
| JardianceEmpagliflozin | 11 | $14,292 |
| FarxigaDapagliflozin Propanediol | 12 | $13,636 |
| Repatha SureclickEvolocumab | 15 | $8,249 |
| Ranolazine ErRanolazine | 31 | $1,967 |
| Atorvastatin Calcium | 94 | $884 |
| Metoprolol Succinate | 39 | $405 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 35 | $384 |
| Valsartan | 18 | $314 |
| Flecainide Acetate | 13 | $180 |
| Metoprolol Tartrate | 46 | $177 |
| Amlodipine Besylate | 32 | $172 |
| Spironolactone | 32 | $150 |
| Nitroglycerin | 14 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $135 | $26,44430 claims |
| NovartisEntresto | $202 | $18,17213 claims |
| Boehringer IngelheimJardiance | $201 | $14,29211 claims |
| AstraZenecaFarxiga | $379 | $13,63612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Worcester
- Deepa JagadeeshWorcester$5.6M
- Jee BangWorcester$2.8M
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.